BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 17044806)

  • 1. Anthracycline cardiotoxicity.
    Jones RL; Swanton C; Ewer MS
    Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
    Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity of conservative treatment of solid tumors].
    Sivak LA; Askol'skiĭ AV; Lial'kin SA; Klimanov MIu; Maĭdanevich NN; Kasap NV
    Lik Sprava; 2011; (3-4):51-9. PubMed ID: 22416364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
    Sadurska E
    Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
    Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.